Hayashi Makoto, Takayasu Hiromi, Tada Mami, Yamazaki Yohei, Tateno Hidetsugu, Tazawa Sakiko, Wakabayashi Aya, Iwasaki Takuya, Tsuchiya Yutaka, Yamashita Jun, Takeda Norikazu, Tomita Shogo, Mori Hiraku, Kokubu Fumio
Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Japan.
Intern Med. 2012;51(17):2411-5. doi: 10.2169/internalmedicine.51.8167. Epub 2012 Sep 1.
A 74-year-old Japanese man with myelodysplastic syndrome (MDS) received chemotherapy with azacitidine. From the second day after starting the administration, he complained of fever, cough and shortness of breath. Chest roentgenography and computed tomography showed consolidations and ground-glass opacities. His symptoms grew from worse to life-threatening. We diagnosed him with azacitidine-induced pneumonitis and began administering corticosteroids. Thereafter, his symptoms and radiographic abnormalities improved. Azacitidine is a hypomethylating agent that improves the survival of MDS patients. Although this drug is commonly well tolerated and rarely causes severe lung injury, it is important to consider the potentially serious adverse effects of azacitidine-induced pneumonitis.
一名74岁患有骨髓增生异常综合征（MDS）的日本男性接受了阿扎胞苷化疗。从开始给药的第二天起，他就出现了发热、咳嗽和呼吸急促的症状。胸部X光和计算机断层扫描显示有实变和磨玻璃影。他的症状逐渐加重，危及生命。我们诊断他为阿扎胞苷诱发的肺炎，并开始给予皮质类固醇治疗。此后，他的症状和影像学异常有所改善。阿扎胞苷是一种去甲基化药物，可提高MDS患者的生存率。尽管这种药物通常耐受性良好，很少引起严重的肺损伤，但考虑到阿扎胞苷诱发肺炎的潜在严重不良反应很重要。
